TGFB1 and pulmonary fibrosis: However, in fibrotic conditions more directly dependent on TGF-β activity, for example, in hepatic, renal or interstitial pulmonary fibrosis, clinical trials with losartan have been successful in slowing fibrosis and reducing of circulating TGF-β (Campistol et al, 1999; Terui et al, 2002; Colmenero et al, 2009).